Renaissance Technologies’s Odonate Therapeutics, Inc. Common Stock ODT Stock Holding History

Renaissance Technologies’s Portfolio ODT Stock Details ODT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-171,349	Closed	-$231K	–	4658
2021 Q4	$231K	Buy	171,349 +138,249	+418%	+$327K	﹤0.01%	3457
2021 Q3	$96K	Buy	+33,100	New	+$110K	﹤0.01%	3324
2021 Q1	–	Sell	-19,320	Closed	-$371K	–	3866
2020 Q4	$371K	Sell	19,320 -15,280	-44%	-$236K	﹤0.01%	2952
2020 Q3	$465K	Buy	+34,600	New	+$980K	﹤0.01%	2836
2020 Q1	–	Sell	-24,100	Closed	-$782K	–	3953
2019 Q4	$782K	Sell	24,100 -1,226	-5%	-$38K	﹤0.01%	2733
2019 Q3	$659K	Sell	25,326 -5,674	-18%	-$190K	﹤0.01%	2763
2019 Q2	$1.14M	Buy	31,000 +11,700	+61%	+$280K	﹤0.01%	2623
2019 Q1	$427K	Buy	19,300 +6,600	+52%	+$115K	﹤0.01%	2982
2018 Q4	$179K	Buy	+12,700	New	+$198K	﹤0.01%	3156

Other funds holding ODT

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

HWAM

Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Simplex Trading Chicago, Illinois $149B AUM 62.07% 1-Year Est. Return

Renaissance Technologies's ODT Position: Q1 2022 in Review

Renaissance Technologies sold out of Odonate Therapeutics, Inc. Common Stock (ODT) in Q1 2022, closing a stake of 171,349 shares — an estimated $231K sold.

Renaissance Technologies first reported a position in ODT in Q4 2018 and held it in 9 quarters. The position peaked at $1.14M in Q2 2019. 8 funds tracked by Wall St. Rank hold ODT as of Q1 2022.

Renaissance Technologies reported no remaining Odonate Therapeutics, Inc. Common Stock position as of Q1 2022 after selling out during the quarter.
Renaissance Technologies sold 171,349 Odonate Therapeutics, Inc. Common Stock shares in Q1 2022, an estimated $231K.
Renaissance Technologies first reported a position in Odonate Therapeutics, Inc. Common Stock in Q4 2018 and held it in 9 quarters.
Renaissance Technologies's Odonate Therapeutics, Inc. Common Stock position peaked at $1.14M in Q2 2019.
8 funds tracked by Wall St. Rank held Odonate Therapeutics, Inc. Common Stock as of Q1 2022.

Based on Renaissance Technologies's 13F filing for Q1 2022, filed 13 May 2022.